Abstract
Cognitive deficits are predictive of long-term social and occupational functional deficits in schizophrenia but are currently without gold-standard treatments. In particular, augmentation of auditory cortical neuroplasticity may represent a rate-limiting first step before addressing higher-order cognitive deficits. We review the rationale for N-methyl-D-aspartate–type glutamate receptor (NMDAR) modulators as treatments for auditory plasticity deficits in schizophrenia, along with potential serum and electroencephalographic target engagement biomarkers for NMDAR function. Several recently published NMDAR-modulating treatment studies are covered, involving D-serine, memantine, and transcranial direct current stimulation. While all three interventions appear to modulate auditory plasticity, direct agonists (D-serine) appear to have the largest and most consistent effects on plasticity, at least acutely. We hypothesize that there may be synergistic effects of combining procognitive NMDAR-modulating approaches with auditory cortical neuroplasticity cognitive training interventions. Future studies should assess biomarkers for target engagement and patient stratification, along with head-to-head studies comparing putative interventions and potential long-term versus acute effects.
Original language | English (US) |
---|---|
Pages (from-to) | 581-590 |
Number of pages | 10 |
Journal | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging |
Volume | 3 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2018 |
Bibliographical note
Publisher Copyright:© 2018 Society of Biological Psychiatry
Keywords
- Biomarker
- Cognition
- MMN
- NMDA
- Plasticity
- Schizophrenia
- Treatment